
Coverage from the Institute for Value-Based Medicine session with Florida Cancer Specialists & Research Institute.
Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.

Coverage from the Institute for Value-Based Medicine session with Florida Cancer Specialists & Research Institute.

The discussion, "Understanding Biomarkers and the Role They Play in Oncology," came during the Community Oncology Alliance Payer Exchange Summit, held October 23-24 in Reston, Virginia.


There is bipartisan support in the Congress for the Community Oncology Alliance's (COA) key agenda items, with hope that some will pass by year’s end.

Community oncology practices are witnessing a new dynamic in which more Medicare-eligible patients are still covered by commercial insurance, according to speakers at the Community Oncology Alliance Payer Exchange Summit, held October 23-24, 2023.

The authors discussed a polymorphism of the LEP gene associated not only with cancer, but also with chronic diseases including obesity and diabetes, offering them a reason to look into the relationship between LEP and myelodysplastic syndrome (MDS).

Investigators evaluated 70 patients in a retrospective study.

The rare disease Fanconi anemia is an inherited bone marrow disorder linked to birth defects that leads to failure of bone marrow, the spongy material inside the bones where stem cells develop.

The survey, completed over 2 weeks in September, follows a similar one released in June.

Katalin Karikó, PhD, and Drew Weissman, MD, PhD, were cited "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19."

The final day of the European Society of Cardiology 2023 Congress featured a joint session with JAMA Cardiology, “Achieving Global Health Equity: A New Challenge in Heart Failure.”

Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, presented by The American Journal of Managed Care® in partnership with Emory's Winship Cancer Institute.

Coverage from a symposium, “Weight loss as a new therapeutic target in HFpEF: dawn of a new era?” that took place August 27 during the European Society of Cardiology 2023 Congress.

The authors found shifting patterns in the effects of obesity, alcohol, and smoking on atrial fibrillation.

Javed Butler, MD, MPH, MBA, presented the analysis based on patient data from the Baylor, Scott, and White health system during the final hours of the European Society of Cardiology 2023 Congress, which concluded Monday.

Results from the FRAIL-AF study, being presented at the European Society of Cardiology 2023 Congress, surprised the investigators.

Study investigators offered updated data from 2 key trials presented in the past year: CLEAR Outcomes in low-density lipoprotein cholesterol and OCEAN(a)-DOSE in lipoprotein (a).

A symposium at the European Society of Cardiology 2023 Congress covered the spectrum from diet and exercise, to medical therapy, to evidence on newer generation stents.

Javed Butler, MD, MPH, MBA, said "hopefully" results from the EMPACT-MI trial should be available within the next few months.

Patients who took the therapy lost weight and recorded some of the best gains in quality of life and physical improvement ever seen in this type of a study.

The interim update in heart failure reflects results from 10 clinical trials that have been published since the 2021 ESC Guidelines were released.

Crystal Denlinger, MD, FACP, incoming CEO of the National Comprehensive Cancer Network (NCCN), talks about the organization’s challenges and solutions to keeping up with the ever-changing oncology landscape and improving patient access to guideline-recommended treatments.

Denlinger, who spent most of her career at Fox Chase Cancer Center before joining the National Comprehensive Cancer Network (NCCN) as its chief scientific officer, took the helm October 9, 2023.

There is no standard treatment in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for patients who have a relapse following allogeneic hematopoietic cell transplantation.

The European Society of Cardiology (ESC) 2023 Congress runs August 25-28 in Amsterdam, the Netherlands.



Full team coverage from the European Hematology Association 2023 Hybrid Congress, which took place June 8-11 in Frankfurt, Germany.

Full coverage of the July 25, 2023, Institute for Value-Based Medicine session in Atlanta, Georgia, held in partnership with Winship Cancer Institute of Emory University.

Coverage from the June 8, 2023, Institute for Value-Based Medicine session in Austin, Texas, held in partnership with Texas Oncology.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
